Aplactin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aplactin

Property Description
Active ingredient Pravastatin (as Pravastatin sodium)
Form Oral tablet
Pharmacological class HMG-CoA reductase inhibitor (Statin)
General purpose Lipid-lowering agent
Origin Semi-synthetic (derived from fermentation)

The medication Aplactin is a prescription-only pharmaceutical containing the active substance Pravastatin (specifically, Pravastatin sodium). Its primary role is to manage high levels of fats in the bloodstream, serving as a lipid-lowering agent and belonging to the class of drugs known as statins. Aplactin is used to assist patients in managing elevated blood lipids.


What Type of Medicine is Aplactin (Pravastatin)?

Aplactin is precisely classified as an HMG-CoA reductase inhibitor, which is the pharmacological name for the entire class of statin drugs. Aplactin is provided as a single-active-ingredient product in the form of an oral tablet for systemic administration. The compound Pravastatin is considered semi-synthetic, noting its origin from a natural precursor derived from the fermentation activity of the microorganism Nocardia autotrophica.

Pravastatin is differentiated from certain other statins by its property of being a hydrophilic statin (water-soluble). This characteristic promotes selective action, meaning the drug is largely confined to the liver cells, the primary site of cholesterol synthesis, rather than distributing broadly throughout non-hepatic tissues. This targeted action is a distinguishing feature, focusing the drug's activity on the main organ responsible for regulating blood cholesterol.


What is the General Purpose of Aplactin?

The general purpose of Aplactin is to help manage high concentrations of lipids, such as hypercholesterolemia and hyperlipidemia. It functions by interfering with the liver's internal production of cholesterol, targeting and lowering levels of low-density lipoprotein cholesterol (LDL-C), commonly termed "bad" cholesterol. By enhancing the clearance of circulating LDL-C and very low-density lipoprotein particles, Aplactin aids in the effort to maintain a healthier blood lipid profile. The typical use scenario involves long-term management to mitigate the health risk associated with persistently elevated blood lipid levels, supporting cardiovascular health.

Regulatory References

  1. Pravastatin - StatPearls - NCBI Bookshelf

What side effects are possible with Aplactin?

Possible Side Effects and Safety Information

The safety profile of Aplactin (based on the regulatory information for its active ingredient, Pravastatin) is officially classified by frequency and body system, as documented by government health authorities like the FDA and EMA. This structure helps patients understand the likelihood and nature of potential reactions.


Adverse Reactions Scope and Frequency

Side effects are categorized by System-Organ-Class (SOC) to identify the body system affected and by frequency using standard regulatory bands (Common, Uncommon, Rare).

Common Adverse Reactions (may affect up to 1 in 10 people):

  • Headache and dizziness.
  • Digestive disturbances, including nausea, vomiting, constipation, or diarrhea.
  • Muscle pain (myalgia) and joint pain (arthralgia).

Uncommon Adverse Reactions (may affect up to 1 in 100 people):

  • Sleep disturbances (insomnia).
  • Skin reactions (rash, itching, hives, or hair loss).
  • Visual disturbances.

Serious Adverse Reactions

Official regulatory labels highlight certain severe, though rare, risks that require attention:

  • Myopathy and Rhabdomyolysis: A serious form of muscle injury that can lead to severe kidney damage. The risk of this reaction is noted as dose-related, generally increasing with higher doses.
  • Liver Dysfunction: Documented cases of severe liver problems, including hepatitis, jaundice, and, rarely, fatal and non-fatal liver failure.

Safety Restrictions and Monitoring

  • Contraindications: Aplactin is generally contraindicated (should not be used) in patients with active liver disease or persistently elevated liver enzyme levels. It is also contraindicated during pregnancy and breastfeeding due to the potential for fetal harm.
  • Monitoring: Regulatory documents mandate routine periodic liver function testing and creatine kinase (CK) level checks, particularly before and during treatment, to monitor for potential liver or muscle damage.

Overdose and Emergency Response

The regulatory documentation for Aplactin (Pravastatin) overdose focuses on muscle toxicity and the risk of severe systemic outcomes. While acute overdose reports are often inconsistent in specific symptoms, the primary concern documented by authorities is the potential for significant muscle damage.

Feature Official Regulatory Statement
Documented Manifestations: Symptoms may include myopathy (muscle pain, tenderness, or weakness), diarrhea, nausea/vomiting, and fever. Laboratory findings often show marked elevation of Creatine Kinase ( CK) levels, exceeding ten times the upper limit of normal, and increased Liver Function Tests.
Severe Outcomes: The most serious, potentially life-threatening event documented is rhabdomyolysis (severe muscle breakdown), which can lead to acute kidney injury secondary to myoglobinuria. Rare fatalities have been associated with this outcome.
Emergency Action Required: Immediate medical attention must be sought upon suspicion of overdose. If an individual is collapsed, having a seizure, or experiencing trouble breathing, emergency services must be contacted immediately.

Official Overdose Management

Treatment is strictly symptomatic and supportive. The regulatory materials note that no specific antidote is known, and hemodialysis is not expected to be effective. Pravastatin therapy must be discontinued immediately. Individuals over age 65 and those with renal impairment are noted as having an increased risk of severe muscle toxicity.

Therapeutic Uses of Aplactin

Main Uses and Benefits of Aplactin

Aplactin is a medication primarily utilized in the management of hypercholesterolemia and the prevention of cardiovascular events. It belongs to a class of drugs known as statins, which work by inhibiting the enzyme HMG-CoA reductase, a key component in the hepatic production of cholesterol.

Primary Indications

The medication is most commonly used for the following conditions:

  • Primary Hypercholesterolemia: Used to lower elevated total cholesterol, LDL cholesterol (often referred to as "bad" cholesterol), and triglycerides in individuals where diet and lifestyle changes alone have not been sufficient.
  • Mixed Dyslipidemia: Helps in balancing lipid profiles in patients with complex cholesterol elevations involving multiple types of fats in the blood.
  • Homozygous Familial Hypercholesterolemia: Acts as an adjunct therapy to lower LDL cholesterol in patients with this specific genetic condition.

Cardiovascular Prevention

Beyond managing lipid levels, Aplactin is utilized to reduce the risk of clinical complications associated with atherosclerosis. This includes:

  • Primary Prevention: Reducing the risk of myocardial infarction (heart attack) and stroke in individuals who have multiple risk factors for heart disease but have not yet developed clinical symptoms.
  • Secondary Prevention: Reducing the risk of recurrence and mortality in patients with established coronary heart disease or a history of cardiovascular events.

Mechanism of Benefit

By reducing the circulating levels of LDL cholesterol, Aplactin helps slow the progression of plaque buildup in the arterial walls. This process, known as stabilizing atherosclerotic plaques, is a critical factor in preventing the rupture of these plaques, which is a leading cause of acute cardiac events. Additionally, the medication may assist in slightly increasing HDL cholesterol (the "good" cholesterol), further contributing to a more favorable lipid balance.

Regulatory References

  1. NIH DailyMed Overview

Eligibility and Restrictions for Use

Aplactin (Pravastatin) eligibility is defined by official regulatory criteria, separating patient groups who are permitted, restricted, or prohibited from use.

Contraindicated Populations

Aplactin is strictly contraindicated and must not be used in the following populations:

  • Patients with active liver disease, including acute liver failure or decompensated cirrhosis.
  • Individuals with unexplained, persistently elevated serum transaminases (liver enzymes).
  • Women who are pregnant or may become pregnant, and nursing mothers (breastfeeding).
  • Patients with known hypersensitivity to Pravastatin or any component of the medication.

Age-Group Eligibility Rules

Age Group Official Regulatory Status
Children under 8 years Safety and efficacy not established
Pediatric Patients (≥ 8 years) Approved for Heterozygous Familial Hypercholesterolemia (HeFH), meeting specific cholesterol criteria
Older Adults (≥ 65 years) Approved for use, but advanced age is cited as a predisposing risk factor for skeletal muscle effects

Eligibility-Related Restrictions

Use requires caution or special consideration for patients with severe renal impairment and those with uncontrolled hypothyroidism. The medicine must also be temporarily discontinued in patients undergoing major surgery or suffering from severe acute conditions like sepsis.

What should I know about interactions with other medicines?

Aplactin (Pravastatin) interacts with other medicines primarily through transporter function and pharmacodynamic synergy, rather than major metabolism via the Cytochrome P450 system. The official interaction profile is structured around managing drug exposure and mitigating the risk of muscle toxicity.

Exposure-Altering Interactions

Certain medicines officially documented as inhibiting hepatic uptake transporters, such as Cyclosporine and select macrolide antibiotics (e.g., Clarithromycin), can significantly increase Pravastatin plasma concentrations. To manage this documented pharmacokinetic interaction, regulatory documents mandate specific maximum daily dosage limits for Pravastatin when these agents are co-administered. Pravastatin's minimal reliance on CYP metabolism means that interactions with typical CYP inhibitors are not expected to be clinically significant.

Pharmacodynamic Risk and Restrictions

Co-administration with other lipid-modifying agents, including fibrates, Niacin (at doses of 1 g/ day or higher), and Colchicine, is associated with an additive, documented increased risk of myopathy and rhabdomyolysis. The combination with Gemfibrozil is a formal restriction that regulatory bodies advise should be avoided.

Timing-Based Rule

The administration of bile acid resins (e.g., Cholestyramine, Colestipol) requires a strict time separation rule, officially documented to prevent reduced absorption and decreased efficacy. Pravastatin must be taken either one hour before or four hours after the resin.

Mechanism of Action

Targeting the Source: Inhibition of Cholesterol Synthesis

Aplactin's mechanism initiates at the molecular level as a competitive inhibitor of the HMG-CoA reductase enzyme, the key controller of the Mevalonate pathway in the liver. By blocking this rate-limiting step, the drug directly suppresses the liver's internal production of new cholesterol, resulting in an intracellular cholesterol deficit that triggers a subsequent physiological response.


Leveraging Cellular Feedback for Systemic Clearance

The resulting cholesterol deficit within the hepatocyte activates a crucial cellular compensatory mechanism by increasing the number of LDL receptors expressed on the cell surface. This enhanced receptor density acts as a molecular pump, accelerating the removal of circulating Low-Density Lipoprotein Cholesterol (LDL-C) particles from the bloodstream, driving the physiological consequence of reduced plasma lipid concentration.


Focused Action and Vascular Signal Modulation

As a hydrophilic statin, Aplactin is selectively concentrated in the liver via active OATP transporters, concentrating its activity primarily in the liver, with limited distribution to peripheral tissue. Beyond lipid regulation, this mechanism also reduces the synthesis of signaling molecules called isoprenoids, which contributes to downstream physiological changes, specifically the modulation of vascular endothelium function.

Dosage and Administration Information

Aplactin, which contains the active substance pravastatin, is a medication intended for chronic management and is administered exclusively via the oral route as a tablet. The tablets are available in multiple strengths: 10 mg, 20 mg, 40 mg, and 80 mg. The standard regimen requires the medicine to be taken once daily. In adults, treatment typically begins with a dose of 40 mg once daily, and the daily intake may be adjusted, but must not exceed the maximum recommended dose of 80 mg. Dosage adjustments are procedural and based on the response to treatment, with reassessments occurring at intervals of four weeks or more.

The timing of the dose is flexible; Aplactin may be taken with or without food and at any time of the day. A key procedural condition exists when co-administering the drug with bile acid sequestrants (resins), requiring Aplactin to be taken either one hour before or four hours after the sequestrant dose. Dosing rules are also modified for specific populations. Patients with severe renal impairment typically begin treatment at 10 mg daily, with the dose restricted to a maximum of 40 mg. For adolescents (ages 14–18), the recommended starting dose is 40 mg, while children (ages 8–13) receive 20 mg daily. Specific restrictions also apply when Aplactin is used with certain other medications, such as limiting the dose to 20 mg when co-administered with Cyclosporine. If a scheduled dose is missed, it should be taken immediately unless it is almost time for the next scheduled dose, in which case the missed dose is skipped to maintain the proper sequence.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Overview of Studies

Research has evaluated whether the action of selectively blocking the activity of a specific signaling protein is associated with an improvement in symptoms for individuals with certain autoimmune conditions. The treatment has been the subject of extensive investigation in various clinical settings.

  • Studies have examined the use of the treatment in both early and advanced stages of the condition.
  • Large-scale Phase III clinical trials have investigated the effect on patient-reported quality of life over periods typically lasting six months to one year.

Clinical Efficacy and Outcomes

A range of studies has evaluated the treatment's impact on disease activity, as measured by standardized scoring systems:

  • Symptom Management: Research explored whether the treatment is associated with changes in symptom severity, such as joint pain and swelling. Findings were reported across several Phase III trials, utilizing measures like the Disease Activity Score (DAS28).
  • Inflammation Markers: Studies have evaluated whether use of the treatment is associated with a reduction in markers of chronic inflammation, such as C-reactive protein (CRP) levels. Evidence remains limited, and further investigation is ongoing in this area.
  • Combination Therapy: Studies have examined the outcomes of using the treatment in combination with standard anti-inflammatory drugs for pain management.

Dosage and Studied Populations

Clinical research has focused on optimizing treatment parameters:

  • Dosage Comparison: Research comparing various dosages has evaluated whether a lower dose is associated with a different side-effect profile and whether it maintains comparable outcomes to a higher dose.

  • Pediatric Use: Studies have included participants aged 12 and above. Research on the use in children under 12 has also been conducted, with findings currently under review.

  • Special Populations: Research has included studies evaluating the use of the treatment in specific adult populations, including individuals with pre-existing conditions such as a history of mild to moderate liver disease.

Frequently Asked Questions (FAQ)

Common questions about Aplactin (FAQ)

Q: How to use Aplactin if I miss a dose?

If a dose of Aplactin is missed, official guidelines suggest taking the dose as soon as it is remembered. However, if it is already close to the time for the next scheduled dose, the missed dose should be skipped, and the regular schedule resumed. Regulatory instructions indicate that two doses should not be taken together to compensate for a missed dose.


Q: Is it normal to have a dry mouth or change in urination while taking Aplactin?

Official labeling lists painful or difficult urination and an increased urge to urinate during the night as less common adverse reactions. While dry mouth is not frequently cited in the core regulatory lists, persistent or concerning changes in bodily function are grounds for consulting a healthcare professional.


Q: How long does it typically take to see an improvement in cholesterol after starting Aplactin?

The official product information indicates that the maximal therapeutic effect of any given dose of Aplactin is usually achieved within four weeks of starting treatment. Healthcare providers often use this four-week window for reassessment related to potential dosage adjustments.


Q: Are there any long-term side effects associated with taking Aplactin regularly?

Aplactin is designed for long-term management of cholesterol. Regulatory warnings highlight that serious, though rare, long-term risks include muscle damage (myopathy/rhabdomyolysis) and potential liver dysfunction. Due to these risks, checks for liver enzymes and creatine kinase levels are often performed before and during prolonged treatment.


Q: Is feeling excessively sleepy a normal side effect of starting Aplactin?

The official adverse reaction lists include sleep disturbances, such as insomnia, as an uncommon side effect. While dizziness is a common side effect, excessive sleepiness or heavy sedation is not typically listed as a frequent adverse reaction in the product information.


Q: What are the concerns about using Aplactin during pregnancy?

Aplactin is strictly contraindicated for use during pregnancy because of the potential for fetal harm. This is due to its mechanism of blocking cholesterol synthesis, a process vital for normal fetal development. Regulatory documents state the medication should not be used by women who are pregnant or who may become pregnant.


Q: Are there specific food restrictions to follow when taking Aplactin?

According to the official product information, Aplactin can be taken with or without food. Unlike some other statins, there are no documented interactions with specific foods, such as grapefruit juice. The only timing restriction is related to its co-administration with bile acid resins.


Q: Is Aplactin the same drug as the one used to treat high prolactin levels?

No. Aplactin contains the active ingredient Pravastatin, which is a statin used to lower high blood cholesterol levels. This is a different class of medicine than those (like Dopamine agonists) used to manage high prolactin levels.


Q: What is the difference between Aplactin and other statins, like Lipitor (Atorvastatin) or Crestor (Rosuvastatin)?

Aplactin (Pravastatin) is categorized as a hydrophilic, or water-soluble, statin, which promotes targeted action primarily within the liver cells. This property distinguishes it from lipophilic (fat-soluble) statins, which tend to distribute more widely throughout non-hepatic tissues.


Q: Are there other brand names that use the same main active ingredients as Aplactin?

The active ingredient in Aplactin is Pravastatin. Since this drug substance is widely available, it is sold under various other brand names and as a generic medicine around the world, as is typical for non-proprietary drug substances.


Q: Can Aplactin cause dizziness or problems with coordination?

Dizziness is listed in the official documents as a commonly reported side effect of Aplactin. However, specific problems with coordination or ataxia are not explicitly listed among the common or uncommon adverse reaction categories.


Q: Is Aplactin considered a 'habit-forming' medicine?

No. Aplactin (Pravastatin) is not classified as a controlled substance by regulatory authorities. It is not considered to be habit-forming or associated with drug dependence.


Q: How long does Aplactin stay in the system after the last dose?

The active substance, Pravastatin, has a relatively short elimination half-life, which is the time it takes for half of the drug to be eliminated from the body. Regulatory information indicates it is typically cleared from the plasma within a few hours.


Q: What are the signs of a serious or uncommon allergic reaction to Aplactin?

Uncommon skin reactions listed in the drug label include hives, itching, and rash. Signs of a more serious allergic reaction may include rapid swelling of the face, lips, tongue, or throat, or blistering and peeling of the skin. Any suspected serious reaction should be addressed by seeking immediate medical attention.


Q: Is Aplactin prescribed for conditions other than high cholesterol, like cardiovascular protection after a heart attack?

Yes. In addition to lowering cholesterol, the medicine is indicated by regulatory bodies to reduce the risk of major cardiovascular events, such as heart attack and stroke, in certain patients who have pre-existing cardiovascular risk factors or established disease.


Q: Are there any known interactions between Aplactin and specific herbal supplements or vitamins?

Official information documents known interactions between Aplactin and high doses of Niacin (Vitamin B3). Regulatory guidance suggests that individuals discuss the use of all concomitant medicines, herbal supplements, and vitamins with a healthcare professional due to the potential for interactions.


Q: What are the official instructions for how to dispose of unused or expired Aplactin?

Unused or expired tablets should be disposed of according to local regulations, often by using community or pharmacy drug take-back programs. Official instructions strictly prohibit discarding the medicine by flushing it down the toilet or pouring it down a drain.


Q: Is there any research on Aplactin's use for conditions other than high cholesterol?

Yes. Beyond its primary role, clinical research has focused on its use in high-risk patient populations, including those with a history of heart attack or specific types of chest pain, to assess its role in reducing the risk of future cardiovascular events.


Q: What is the scientific evidence supporting Aplactin's effectiveness for cardiovascular disease prevention?

The effectiveness of Pravastatin in preventing cardiovascular events is supported by large, long-term clinical trials such as the LIPID and MEGA studies. These trials demonstrated its ability to reduce the risk of fatal and non-fatal cardiovascular events in high-risk patients with elevated cholesterol or existing disease.


Q: What are the clinical trials that compare Aplactin to other statins?

While regulatory documents provide detailed information on the chemical and functional differences between Pravastatin and other statins, official labeling generally focuses on its efficacy against placebo or diet. Comparative studies often highlight pharmacokinetic properties, such as its water-solubility and liver-selective action.


Q: Can Aplactin affect a person's ability to drive or operate machinery?

Yes, it can. Since dizziness is listed as a common side effect of Aplactin, official product information advises that this may impair a person's ability to drive or use heavy machinery. Individuals who experience dizziness should use caution when performing such activities.


Q: Is Aplactin known to cause any emotional or mood changes?

Regulatory information lists anxiety, nervousness, or sadness as less common or rare side effects of the medication. Experiencing significant emotional or mood changes while using this drug is a reason to notify a healthcare provider.


Q: Do you need a prescription to get Aplactin?

Yes. Aplactin (Pravastatin) is classified as a prescription-only pharmaceutical and requires a valid prescription from a licensed healthcare provider.

How should Aplactin be stored and disposed of?

How to Store and Dispose of Aplactin (Pravastatin Sodium)

The official labeling for Aplactin tablets (Pravastatin sodium) mandates strict storage and disposal compliance to maintain product integrity and environmental safety.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F).
Protection Keep the container tightly closed to protect the medicine from moisture; avoid excessive heat.
Packaging Store only in the original container to maintain stability.
Child Safety Keep out of the sight and reach of children at all times.

Disposal Instructions

Unused or expired Aplactin must be disposed of according to local regulations, often through community or pharmacy drug take-back programs. The official instructions strictly prohibit discarding the medicine by flushing it down the toilet or pouring it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aplactin found in:

A-Z Index: